The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
AMPK activation counteracts cardiac hypertrophy by reducing O-GlcNAcylation
Open accessAbstract
AMP-activated protein kinase (AMPK) has been shown to inhibit cardiac hypertrophy. Here, we show that submaximal AMPK activation blocks cardiomyocyte hypertrophy without affecting downstream targets previously suggested to be involved, such as p70 ribosomal S6 protein kinase, calcineurin/nuclear factor of activated T cells (NFAT) and extracellular signal-regulated kinases. Instead, cardiomyocyte hypertrophy is accompanied by increased protein O-GlcNAcylation, which is reversed by AMPK activation. Decreasing O-GlcNAcylation by inhibitors of the glutamine:fructose-6-phosphate aminotransferase (GFAT), blocks cardiomyocyte hypertrophy, mimicking AMPK activation. Conversely, O-GlcNAcylation-inducing agents counteract the anti-hypertrophic effect of AMPK. In vivo, AMPK activation prevents myocardial hypertrophy and the concomitant rise of O-GlcNAcylation in wild-type but not in AMPKα2-deficient mice. Treatment of wild-type mice with O-GlcNAcylation-inducing agents reverses AMPK action. Finally, we demonstrate that AMPK inhibits O-GlcNAcylation by mainly controlling GFAT phosphorylation, thereby reducing O-GlcNAcylation of proteins such as troponin T. We conclude that AMPK activation prevents cardiac hypertrophy predominantly by inhibiting O-GlcNAcylation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The progression from hypertension to congestive heart failure
Levy, D. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03530440037034 · Cited by 2,155 · cited 1×
“Nature Communications, Nature Publishing Group, 2018, 9 (1), pp.”
Metformin: from mechanisms of action to therapies
Foretz, M., Guigas, B., Bertrand, L., Pollak, M., & Viollet, B. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.09.018 · Cited by 1,501
Self-citationAdiponectin-mediated modulation of hypertrophic signals in the heart
Shibata, R., Ouchi, N., Ito, M., Kihara, S., Shiojima, I., Pimentel, D. R., Kumada, M., Sato, K., Schiekofer, S., Ohashi, K., et al. (2004) · Nature Medicine · doi:10.1038/nm1137 · Cited by 671
Xie, Z., Lau, K., Eby, B., Lozano, P., He, C., Pennington, B., Li, H., Rathi, S., Dong, Y., Tian, R., et al. (2011) · Diabetes · doi:10.2337/db10-0351 · Cited by 490
Chou, T.-Y., Hart, G. W., & Dang, C. V. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.32.18961 · Cited by 453
Chan, A. Y. M., Soltys, C.-L. M., Young, M. E., Proud, C. G., & Dyck, J. R. B. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m403528200 · Cited by 331
AMPK: Lessons from transgenic and knockout animals
Viollet, B. (2009) · Frontiers in bioscience · doi:10.2741/3229 · Cited by 314
Self-citationHu, P., Zhang, D., Swenson, L., Chakrabarti, G., Abel, E. D., & Litwin, S. E. (2003) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00108.2003 · Cited by 245
Resveratrol inhibits cardiac hypertrophy via AMP-activated protein kinase and Akt
Chan, A. Y. M., Dolinsky, V. W., Soltys, C.-L. M., Viollet, B., Baksh, S., Light, P. E., & Dyck, J. R. B. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m802869200 · Cited by 244
Self-citationRamirez-Correa, G. A., Jin, W., Wang, Z., Zhong, X., Gao, W. D., Dias, W. B., Vecoli, C., Hart, G. W., & Murphy, A. M. (2008) · Circulation Research · doi:10.1161/circresaha.108.184978 · Cited by 145
Cited by
AMP-activated protein kinase: the current landscape for drug development
Steinberg, G. R., & Carling, D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0019-2 · Cited by 754
Metabolic remodelling in heart failure
Bertero, E., & Maack, C. (2018) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0044-6 · Cited by 706
Obesity cardiomyopathy: evidence, mechanisms, and therapeutic implications
Ren, J., Wu, N. N., Wang, S., Sowers, J. R., & Zhang, Y. (2021) · Physiological Reviews · doi:10.1152/physrev.00030.2020 · Cited by 370
Ribosome biogenesis in disease: new players and therapeutic targets
Jiao, L., Liu, Y., Yu, X.-Y., Pan, X., Zhang, Y., Tu, J., Song, Y.-H., & Li, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01285-4 · Cited by 313
FNDC5/Irisin inhibits pathological cardiac hypertrophy
Yu, Q., Kou, W., Xu, X., Zhou, S., Luan, P., Xu, X., Li, H., Zhuang, J., Wang, J., Zhao, Y., et al. (2019) · Clinical Science · doi:10.1042/cs20190016 · Cited by 115
Metadata
- Authors
- Gélinas, R., Mailleux, F., Dontaine, J., Bultot, L., Demeulder, B., Ginion, A., Daskalopoulos, E. P., Esfahani, H., Dubois-Deruy, E., Lauzier, B., Gauthier, C., Olson, A. K., Bouchard, B., Des Rosiers, C., Viollet, B., Sakamoto, K., Balligand, J.-L., Vanoverschelde, J.-L., Beauloye, C., Horman, S., & Bertrand, L.
- Venue
- Nature Communications
- Published
- 2018-01-25
- Volume
- 9
- Issue
- 1
- Pages
- 374-374
- ISSN
- 2041-1723 (ISSN-L)
- OpenAlex
- W2792807715
- Cited by
- 253
- References
- 10
- FWCI
- 7.85
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: AMPK activation counteracts cardiac hypertrophy by reducing O-GlcNAcylation. https://app.cochat.ai/papers/10.1038/s41467-017-02795-4
- The paper
- Gélinas, R., Mailleux, F., Dontaine, J., Bultot, L., Demeulder, B., Ginion, A., Daskalopoulos, E. P., Esfahani, H., Dubois-Deruy, E., Lauzier, B., Gauthier, C., Olson, A. K., Bouchard, B., Des Rosiers, C., Viollet, B., Sakamoto, K., Balligand, J.-L., Vanoverschelde, J.-L., Beauloye, C., . . . Bertrand, L. (2018). AMPK activation counteracts cardiac hypertrophy by reducing O-GlcNAcylation. Nature Communications. https://doi.org/10.1038/s41467-017-02795-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.